June 4, 2020—Qiagen announced the launch of novel solutions designed to enable faster, better analysis of genomic variations in cancer, showcasing its portfolio at the 2020 American Society of Clinical Oncology annual meeting, which was held virtually May 29–31.
The new QCI Interpret One software solution adds to the Qiagen Clinical Insights portfolio. QCI Interpret One delivers variant- and disease-specific evidence for every variant in any somatic panel, the company said in a press release, backing each classification with the latest peer-reviewed publications and oncologist-reviewed interpretation summaries. It combines the former N-of-One interpretation summaries with Qiagen’s QCI Interpret structured variant interpretation database.
Designed to support the growing demand for workflow and assay consolidation, the QIAseq Multimodal technology enables the consolidation of two NGS-based DNA and RNA variant profiling workflows into one and also enables scalable and parallel interrogation of up to thousands of targets in one enrichment step in one single tube. Ideal for comprehensive genomic profiling and biomarker discovery, the 1.44 Mb panel consists of more than 600 target genes and fusions involved in the onset, progression, and treatment response across different cancer types, as well as microsatellite instability markers. Hands-on and turnaround time is one day.
The novel QIAseq Targeted Methyl panels are NGS-based products for targeted methylation analysis. The solutions offer one-day workflows and data analysis pipelines for predesigned and custom-tailored panels in a range of cancer applications, designed specifically for low-input samples including liquid biopsy and FFPE.